Kinoshita Y et al (2004) Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer 3(2):83–86
Article
PubMed
Google Scholar
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
Article
PubMed
Google Scholar
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011) EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder, the 2011 update. European Urol. 59(6):997–1008
Article
Google Scholar
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
Article
PubMed
Google Scholar
Czerniak B, Dinney C, McConkey (2016) Origins of bladder cancer. Annu Rev Pathol. 11:149–74
Bellmunt J, Petrylak DP (2012) New therapeutic challenges in advanced bladder cancer. In: Seminars in oncology. Elsevier
Burger M et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 63(2):234–241
Article
PubMed
Google Scholar
Cheung G et al (2013) Recent advances in the diagnosis and treatment of bladder cancer. BMC Med 11(1):13
Article
PubMed
PubMed Central
Google Scholar
Martyn-Hemphill C et al (2013) Recent advances in diagnosis and treatment of transitional cell carcinoma of the bladder. Int J Surg 11(9):749–752
Article
PubMed
Google Scholar
Dovedi SJ, Davies BRJC, Reviews M (2009) Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 28(3–4):355
Article
CAS
PubMed
Google Scholar
Hartge P et al (1990) Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 82(20):1636–1640
Article
CAS
PubMed
Google Scholar
Mojarrad M, Moghbeli M (2020) Genetic and molecular biology of bladder cancer among Iranian patients. Mol Genet Genomic Med 8(6):e1233
Article
PubMed
PubMed Central
Google Scholar
Jemal A et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225–249
Article
PubMed
Google Scholar
Steele CB et al (2017) Prostate cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 123:5160–5177
Article
PubMed
Google Scholar
Shavers VL, Underwood W, Moser RP (2009) Race/ethnicity and the perception of the risk of developing prostate cancer. Am J Prev Med. 37(1):64–67
Article
PubMed
PubMed Central
Google Scholar
Ghayour-Mobarhan M, Ferns GA, Moghbeli M (2020) Genetic and molecular determinants of prostate cancer among Iranian patients: An update. Crit Rev Clin Lab Sci 57(1):37–53
Article
CAS
PubMed
Google Scholar
Manning G et al (2002) The protein kinase complement of the human genome. Science. 298(5600):1912–34
Article
CAS
PubMed
Google Scholar
Hubbard MJ, Cohen P (1993) On target with a new mechanism for the regulation of protein phosphorylation. Trends Biochem Sci. 18(5):172–177
Article
CAS
PubMed
Google Scholar
Nattel S et al (2007) Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev. 87(2):425–456
Article
CAS
PubMed
Google Scholar
Moghbeli M et al (2013) Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol 30(2):516
Article
PubMed
CAS
Google Scholar
Moghbeli M et al (2019) ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biol Res 52(1):2
Article
PubMed
PubMed Central
Google Scholar
Zangouei AS et al (2020) Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal 18(1):127
Article
CAS
PubMed
PubMed Central
Google Scholar
Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. New England J Med. 353(2):172–187
Article
CAS
Google Scholar
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297
Article
CAS
PubMed
Google Scholar
Shi Z et al (2017) Exploring the key genes and pathways of osteosarcoma with pulmonary metastasis using a gene expression microarray. Molec Med Rep. 16(5):7423–7431
Article
CAS
Google Scholar
Nishikawa R et al (2015) MicroRNA-205 inhibits cancer cell migration and invasion via modulation of centromere protein F regulating pathways in prostate cancer. Int J Urol 22(9):867–877
Article
CAS
PubMed
Google Scholar
Gandellini P et al (2014) miRNAs in tumor radiation response: bystanders or participants? Trends Mol Med 20(9):529–539
Article
CAS
PubMed
Google Scholar
Leonetti A et al (2019) MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. Drug Resist Updat 42:1–11
Article
PubMed
Google Scholar
Ohno S et al (2013) Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 21(1):185–191
Article
CAS
PubMed
Google Scholar
Yokoi T, Nakajima M (2013) microRNAs as mediators of drug toxicity. Annu Rev Pharmacol Toxicol 53:377–400
Article
CAS
PubMed
Google Scholar
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103–141
Article
CAS
PubMed
Google Scholar
Vanacore D et al (2017) Micrornas in prostate cancer: an overview. Oncotarget 8(30):50240
Article
PubMed
PubMed Central
Google Scholar
Braicu C et al (2015) Clinical and pathological implications of miRNA in bladder cancer. Int J Nanomedicine 10:791
Article
PubMed
PubMed Central
CAS
Google Scholar
Brighenti M (2015) MicroRNA and MET in lung cancer. Ann Transl Med 3(5):68
PubMed
PubMed Central
Google Scholar
Gomez GG et al (2013) Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Cancer Biol Med 10(4):192–205
CAS
PubMed
PubMed Central
Google Scholar
Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Chem. 265(14):7709–7712
Article
CAS
PubMed
Google Scholar
Sarkar S et al (2010) ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 9(8):592–603
Article
CAS
PubMed
Google Scholar
Guo X et al (2011) AKT activation by Pdcd4 knockdown up-regulates cyclin D1 expression and promotes cell proliferation. Genes Cancer 2(8):818–828
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou Y et al (2013) MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 47(5):423–432
Article
CAS
PubMed
Google Scholar
Xu B et al (2016) hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR. Tumour Biol 37(10):14141–14151
Article
CAS
PubMed
Google Scholar
Lu Y et al (2016) The long non-coding RNA NEAT1 regulates epithelial to mesenchymal transition and radioresistance in through miR-204/ZEB1 axis in nasopharyngeal carcinoma. Tumor Biol. 37(9):11733–11741
Article
CAS
Google Scholar
Zhang P et al (2014) miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 5(1):1–10
Article
Google Scholar
Zhang P et al (2014) ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 16(9):864–875
Article
CAS
PubMed
PubMed Central
Google Scholar
El Bezawy R et al (2017) miR-875–5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. Cancer Lett. 395:53–62
Article
PubMed
CAS
Google Scholar
Pettitt J (2005) The cadherin superfamily, in WormBook: the online review of C. elegans Biology. WormBook
Forghanifard MM et al (2017) TWIST1 upregulates the MAGEA4 oncogene. Mol Carcinog 56(3):877–885
Article
CAS
PubMed
Google Scholar
Adam L et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15(16):5060–5072
Article
CAS
PubMed
PubMed Central
Google Scholar
Paez JG et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500
Article
CAS
PubMed
Google Scholar
Nathanson DA et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166):72–76
Article
CAS
PubMed
Google Scholar
Matar P et al (2004) Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10(19):6487–6501
Article
CAS
PubMed
Google Scholar
Gelsomino F et al (2013) Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. J Clin Oncol 31(26):3291–3293
Article
PubMed
CAS
Google Scholar
Schulze A et al (2004) The transcriptional response to Raf activation is almost completely dependent on mitogen-activated protein kinase kinase activity and shows a major autocrine component. Molec Biol Cell. 15(7):3450–3463
Article
CAS
PubMed
PubMed Central
Google Scholar
McCarthy SA et al (1995) Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Develop. 9(16):1953–1964
Article
CAS
PubMed
Google Scholar
Schwartz YB, Pirrotta V (2008) Polycomb complexes and epigenetic states. Curr Opin Cell Biol. 20(3):266–273
Article
CAS
PubMed
Google Scholar
Siu MK et al (2014) Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget 5(11):3770
Article
PubMed
PubMed Central
Google Scholar
Qin Q et al (2012) Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 22(1):90–106
Article
CAS
PubMed
Google Scholar
Chang Y-S et al (2015) EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res 75(15):3077–3086
Article
CAS
PubMed
PubMed Central
Google Scholar
Flanagan L et al (2015) High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol 10(1):131
Article
CAS
PubMed
PubMed Central
Google Scholar
Holcik M et al (2000) Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19(36):4174–4177
Article
CAS
PubMed
Google Scholar
Hu Y et al (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9(7):2826–2836
CAS
PubMed
Google Scholar
Amantana A et al (2004) X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3(6):699–707
Article
CAS
PubMed
Google Scholar
Cao Z et al (2014) X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis. Oncotarget 5(16):7126
Article
PubMed
PubMed Central
Google Scholar
Lee S et al (2014) A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells. Cell Death Dis 5(10):e1477–e1477
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang C et al (2017) XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell. J Hematol Oncol 10(1):6
Article
PubMed
PubMed Central
CAS
Google Scholar
Tao J et al (2012) microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep 27(6):1967–1975
CAS
PubMed
Google Scholar
Kibel AS, et al (1998) Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 58(24):5652–5655
CAS
PubMed
Google Scholar
Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11–22
Article
CAS
PubMed
PubMed Central
Google Scholar
Tsai Y-C et al (2017) Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6. Cancer Lett. 384:1–8
Article
CAS
PubMed
Google Scholar
Lin X, Wang YJC, Oncology T (2018) Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression. Clin Transl Oncol 20(11):1400–1407
Article
CAS
PubMed
Google Scholar
Hinman MN, Lou H (2008) Diverse molecular functions of Hu proteins. Cell Mol Life Sci. 65(20):3168–3181
Article
CAS
PubMed
PubMed Central
Google Scholar
Niesporek S et al (2008) Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol. 32(2):341–347
CAS
PubMed
Google Scholar
Barbisan F et al (2009) Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol. 56(1):105–112
Article
CAS
PubMed
Google Scholar
Epis MR et al (2011) The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 286(48):41442–41454
Article
CAS
PubMed
PubMed Central
Google Scholar
Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5(5):341–354
Article
CAS
PubMed
Google Scholar
Wang X, et al (2016) miR-148a-3p represses proliferation and EMT by establishing regulatory circuits between ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis 7(12):e2503
Article
CAS
PubMed
PubMed Central
Google Scholar
Mahe M, et al (2018) An FGFR 3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Mol Med 10(4):e8163
Article
PubMed
PubMed Central
CAS
Google Scholar
Katoh M (2016) Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci 37(12):1081–1096
Article
CAS
PubMed
Google Scholar
Mao W et al (2019) Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res 38(1):1–14
Article
CAS
Google Scholar
Wu D et al (2015) microRNA-99a inhibits cell poliferation, colony formation ability, migration and invasion by targeting fibroblast growth factor receptor 3 in prostate cancer. Mol Med Rep. 11(2):1469–1475
Article
CAS
PubMed
Google Scholar
Pollard C, Smith SC, Theodorescu D (2010) Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med 12:e10
Article
PubMed
PubMed Central
CAS
Google Scholar
Castillo-Martin M et al. Molecular pathways of urothelial development and bladder tumorigenesis. In Urologic oncology: seminars and original investigations. Elsevier; 2010.
L'Hôte CG, Knowles MA (2005) Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 304(2):417–431
Article
PubMed
CAS
Google Scholar
Brahimi-Horn MC, Pouysségur J (2009) HIF at a glance. J Cell Sci. 122(8):1055–1057
Article
CAS
PubMed
Google Scholar
Blick C et al (2013) Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer. British J Cancer. 109(1):50–59
Article
CAS
Google Scholar
Long J et al (2016) MicroRNA-15a-5p suppresses cancer proliferation and division in human hepatocellular carcinoma by targeting BDNF. Tumour Biol 37(5):5821–5828
Article
CAS
PubMed
Google Scholar
Gao L et al (2018) MiR-1-3p inhibits cell proliferation and invasion by regulating BDNF-TrkB signaling pathway in bladder cancer. Neoplasma 65(1):89–96
Article
CAS
PubMed
Google Scholar
Birchmeier C et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925
Article
CAS
PubMed
Google Scholar
Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 11(12):834–848
Article
CAS
PubMed
Google Scholar
O’Brien LE et al (2004) ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. Dev Cell 7(1):21–32
Article
CAS
PubMed
Google Scholar
Graziani A et al (1991) The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 266(33):22087–22090
Article
CAS
PubMed
Google Scholar
Boccaccio C et al (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391(6664):285–288
Article
CAS
PubMed
Google Scholar
Monga SP et al (2002) Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62(7):2064–2071
CAS
PubMed
Google Scholar
Humphrey PA et al (1995) Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147(2):386
CAS
PubMed
PubMed Central
Google Scholar
Knudsen BS et al (2002) High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60(6):1113–1117
Article
PubMed
Google Scholar
Hagman Z et al (2013) The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer 109(5):1271–1278
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu X et al (2016) c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial–mesenchymal transition in bladder cancer by regulating Akt/GSK-3 β/Snail signaling. Cell Death Dis 7(2):e2088–e2088
Article
CAS
PubMed
PubMed Central
Google Scholar
Kim Y-W et al (2015) The c-MET network as novel prognostic marker for predicting bladder cancer patients with an increased risk of developing aggressive disease. PLoS One 10(7):e0134552
Article
PubMed
PubMed Central
CAS
Google Scholar
Cil I et al (2017) Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c-MET amplification. J BUON 22(1):279
PubMed
Google Scholar
Qiu J et al (2019) Increased miR-323a induces bladder cancer cell apoptosis by suppressing c-Met. Kaohsiung J Med Sci 35(9):542–549
Article
CAS
PubMed
Google Scholar
Xu X et al (2013) MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 36(1):62–68
Article
CAS
PubMed
PubMed Central
Google Scholar
Chiyomaru T et al (2015) Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer. Int J Oncol 46(2):487–496
Article
CAS
PubMed
Google Scholar
Schee K et al (2012) Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12(1):505
Article
CAS
PubMed
PubMed Central
Google Scholar
Luo L et al (2012) MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol 29(3):1681–1686
Article
CAS
PubMed
Google Scholar
Hao Y et al (2011) Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) 4(7):1073–1083
Article
CAS
Google Scholar
Yeh C-Y et al (2011) Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras-and Src-independent mechanism in human bladder cancer. BMC Cancer. 11(1):1–12
Article
CAS
Google Scholar
Hu Z et al (2013) MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun 435(1):82–87
Article
CAS
PubMed
Google Scholar
Li J et al (2017) MET/SMAD3/SNAIL circuit mediated by miR-323a-3p is involved in regulating epithelial–mesenchymal transition progression in bladder cancer. Cell Ceath Dis 8(8):e3010–e3010
Article
CAS
Google Scholar
Gao S et al (2019) MiR-1 inhibits prostate cancer PC3 cells proliferation through the Akt/mTOR signaling pathway by binding to c-Met. Biomed Pharmacother. 109:1406–1410
Article
CAS
PubMed
Google Scholar
Heidegger I et al (2015) The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Lett. 367(2):113–121
Article
CAS
PubMed
Google Scholar
Ozkan EE. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol. 2011;344(1–2):1–24.
Article
CAS
PubMed
Google Scholar
O’bryan J, et al (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11(10):5016–5031
Google Scholar
Paccez JD et al (2013) The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene. 32(6):689
Article
CAS
PubMed
Google Scholar
Nam RK et al (2019) MicroRNA-139 is a predictor of prostate cancer recurrence and inhibits growth and migration of prostate cancer cells through cell cycle arrest and targeting IGF1R and AXL. Prostate. 79(12):1435–1451
Article
CAS
Google Scholar
Zhu Z et al (2014) MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells. FEBS Lett 588(17):3180–3185
Article
CAS
PubMed
Google Scholar
Hellawell G et al (2003) Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int. 91(3):271–277
Article
CAS
PubMed
Google Scholar
Krueckl SL et al (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64(23):8620–8629
Article
CAS
PubMed
Google Scholar
Nickerson T et al (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61(16):6276–6280
CAS
PubMed
Google Scholar
Wang L-N et al (2013) The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. Asian J Androl 15(6):753
Article
CAS
PubMed
PubMed Central
Google Scholar
Pendergast AM (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res. 85(85):51–100
Article
CAS
PubMed
Google Scholar
Tsuji T (2004) Physiological and pathological roles of α3β1 integrin. J Membrane Biol. 200(3):115–132
Article
CAS
Google Scholar
Arora S et al (2013) MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One 8(11):e78023
Greuber EK et al (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13(8):559–571
Article
CAS
PubMed
PubMed Central
Google Scholar
Colicelli J (2010) ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal 3(139):re6–re6
Article
PubMed
PubMed Central
CAS
Google Scholar
Zandy NL (2008) Abl tyrosine kinases mediate intercellular adhesion. Duke University
Peacock JG et al (2007) The Abl-related gene tyrosine kinase acts through p190RhoGAP to inhibit actomyosin contractility and regulate focal adhesion dynamics upon adhesion to fibronectin. Mol Biol Cell 18(10):3860–3872
Article
CAS
PubMed
PubMed Central
Google Scholar
Qiang XF et al (2014) miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J Cell Biochem 115(7):1269–1276
Article
CAS
PubMed
Google Scholar
Fizazi K (2007) The role of Src in prostate cancer. Ann Oncol 18(11):1765–1773
Article
CAS
PubMed
Google Scholar
Ingley E (2012) Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal 10(1):1–11
Article
CAS
Google Scholar
Chang CY-M, Kung H-J, Evans CPJN (2007) Nonreceptor tyrosine kinases in prostate. Neoplasia 9(2):90–100
Article
CAS
PubMed
PubMed Central
Google Scholar
Saini S et al (2014) Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther 13(7):1952–1963
Article
CAS
PubMed
PubMed Central
Google Scholar
Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32):8253–8261
Article
CAS
PubMed
Google Scholar
Zong Y, Goldstein AS (2013) Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nat Rev Urol 10(2):90–98
Article
CAS
PubMed
Google Scholar
Bromann PA, Korkaya H, Courtneidge SA (2004) The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23(48):7957–7968
Article
CAS
PubMed
Google Scholar
Carver BS et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5):575–586
Article
CAS
PubMed
PubMed Central
Google Scholar
Kinkade CW et al (2008) Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 118(9):3051–3064
CAS
PubMed
PubMed Central
Google Scholar
Mulholland DJ et al (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6):792–804
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu Y-N et al (2015) Loss of androgen-regulated microRNA 1 activates SRC and promotes prostate cancer bone metastasis. Mol Cell Biol 35(11):1940–1951
Article
CAS
PubMed
PubMed Central
Google Scholar
Yang YA, Yu JJP (2013) EZH2, an epigenetic driver of prostate cancer. Protein Cell 4(5):331–341
Article
CAS
PubMed
PubMed Central
Google Scholar
Xu K et al (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338(6113):1465–1469
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi X-B et al (2015) miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src. Cancer Res 75(24):5309–5317
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhang H et al (2013) Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway. Cancer Gene Ther 20(11):622–629
Article
CAS
PubMed
Google Scholar
Maung K et al (1999) Requirement for focal adhesion kinase in tumor cell adhesion. Oncogene 18(48):6824–6828
Article
CAS
PubMed
Google Scholar
Liu H et al (2018) Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. Mol Cancer 17(1):161
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu L et al (2016) Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES 1 expression in thyroid cancer. FEBS J 283(12):2326–2339
Article
CAS
PubMed
Google Scholar
Yamamoto H et al (2016) Yes1 is the key molecule for the resistance to trastuzumab in breast cancer, and dasatinib overcomes the resistance. AACR
Chen L, Cao H, Feng Y (2018) MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J Urol 36(3):357–365
Article
CAS
PubMed
Google Scholar
Ottoson NC et al (2001) Cutting edge: T cell migration regulated by CXCR4 chemokine receptor signaling to ZAP-70 tyrosine kinase. J Immunol 167(4):1857–1861
Article
CAS
PubMed
Google Scholar
Soede RD et al (1999) LFA-1 to LFA-1 signals involve ζ-associated protein-70 (ZAP-70) tyrosine kinase: relevance for invasion and migration of a T cell hybridoma. J Immunol 163(8):4253–4261
Article
CAS
PubMed
Google Scholar
Richardson SJ et al (2006) ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 107(9):3584–3592
Article
CAS
PubMed
Google Scholar
Fu D et al (2016) MiR-631/ZAP70: A novel axis in the migration and invasion of prostate cancer cells. Biochem Biophys Res Commun 469(3):345–351
Article
CAS
PubMed
Google Scholar
Brauer PM, Tyner AL (2010) Building a better understanding of the intracellular tyrosine kinase PTK6—BRK by BRK. Biochimica et Biophysica Acta (BBA)-Rev. Cancer 1806(1):66–73
CAS
Google Scholar
Zheng Y, Tyner AL (2013) Context-specific protein tyrosine kinase 6 (PTK 6) signalling in prostate cancer. Eur J Clin Invest. 43(4):397–404
Article
CAS
PubMed
PubMed Central
Google Scholar
Wozniak DJ et al (2017) PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer. Nature communications 8(1):1–13
Article
CAS
Google Scholar
Cagle P et al (2019) MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells. Sci Rep 9(1):1–13
Article
CAS
Google Scholar
Yeasmin S et al (2011) MKK4 acts as a potential tumor suppressor in ovarian cancer. Tumor Biol 32(4):661–670
Article
CAS
Google Scholar
Ishikawa M et al (2010) Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer. Oncology 79(3–4):238–246
Article
CAS
PubMed
Google Scholar
Wan X et al (2016) Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression. Int J Biochem Cell Biol 79:249–260
Article
CAS
PubMed
Google Scholar
Zhu Y et al (2018) MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogena-ctivated protein kinase kinase 4. Mol Med Rep 17(3):4803–4810
CAS
PubMed
Google Scholar
Avruch J et al (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56:127–155
Article
CAS
PubMed
Google Scholar
Ahmad I et al (2011) Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2(3):e124–e124
Article
CAS
PubMed
PubMed Central
Google Scholar
Moon RT et al (2004) WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 5(9):691–701
Article
CAS
PubMed
Google Scholar
Hirata H et al (2012) MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis 33(1):41–48
Article
CAS
PubMed
Google Scholar
Khan N et al (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10(3):475–510
Article
CAS
PubMed
Google Scholar
Fremont L (2000) Biological effects of resveratrol. Life Sci 66(8):663–673
Article
CAS
PubMed
Google Scholar
Maxwell S, Cruickshank A, Thorpe GJTL (1994) Red wine and antioxidant activity in serum. Lancet 344(8916):193–194
Article
CAS
PubMed
Google Scholar
Harper CE et al (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28(9):1946–1953
Article
CAS
PubMed
Google Scholar
Bitomsky N, Böhm M, Klempnauer K-HJO (2004) Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 23(45):7484–7493
Article
CAS
PubMed
Google Scholar
Egan SM et al (2017) miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget 8(40):67626
Article
PubMed
PubMed Central
Google Scholar
Wang N et al (2015) Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK–mediated phosphorylation of Akt. Clin Cancer Res 21(20):4676–4685
Article
CAS
PubMed
Google Scholar
Zheng X-M et al (2019) MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3. Int J Oncol 54(2):443–454
CAS
PubMed
Google Scholar